I do not expect any major changes until at least Wednesday. That assumes that we have some sort of election clarity (hopefully). Even then I am not sure what is best for the sector. I would usually assume that a Republican win would be better but some are naturally getting nervous about RFK role in […]
Halloween Biotech Update
Happy Halloween and it is a little scary out there right now, although only a little. We still are in the middle of the range and with the election coming next week, I am not convinced we get a significant move before that clarity (although I also doubt we get full clarity after the election). […]
October 30th Biotech Update
Not much to say about the sector as we continue in the range and are a little higher today as we move towards the upper end of the range. Of course, it is always nicer to be near the higher end than the lower end but as always the expectation should always be that we […]
October 29th Biotech Update
Tell me if you have heard this before but the sector appears to be range bound. There is nothing that has happened to indicate anything other than a range bound market, On the positive side, we have moved away from the lower end of the range and are much closer to the middle but I […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
